Ongoing research in the field of synucleinopathies aims to prevent or halt disease progression, with various approaches under investigation, including immunotherapy, gene therapy, stem cell therapy, and targeting alpha‐synuclein aggregation. Here, SNCA is linked to synucleinopathy.